James Rolke's Common Stock Acquisition in Revelation Biosciences, Inc.

On October 29, 2025, James Rolke, the Chief Executive Officer of Revelation Biosciences, Inc., acquired 390,614 shares of common stock at a price of $1.28 per share. This transaction was part of a restricted stock grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. Following this transaction, Rolke's total ownership in the company increased to 400,660 shares. The filing, submitted on October 30, 2025, was signed by J.P. Galda as attorney-in-fact for James Rolke. This transaction highlights Rolke's continued investment in the company.